Explore the Agenda
Welcome to the post-conference Future Technologies & Innovations Day. You can either attend our Future of Induced Proximity Track or our Latest Tools & Technologies Track. If you have any questions about the layout or agenda, feel free to reach out to us at info@hansonwade.com.
Research Breakthroughs Day
Monday, October 26
Pipeline Progression Day 1
Tuesday, October 27
Pipeline Progression Day 2
Wednesday, October 28
Future Technologies & Innovations Day
Thursday, October 29
Future of Induced Proximity Track
7:30 am Check In & Refreshments
8:20 am Chair’s Opening Remarks
Developing Next-Generation Degraders to Achieve Tissue-Specific Protein Degradation & Enable Development of Clinically Impactful Therapies
8:30 am Degrader-Antibody Conjugates: Proof of Concept Through Design of a Potent BRD4 Degrading Linker-Payload
- A modular linker strategy was developed to screen BRD4 degrader antibody conjugates (DACs)
- Payload potency correlates well with DAC activity
- Potent DACs to multiple target antigens were identified; however, pre-clinical toxicology limits further development
9:00 am Next-Generation Degrader Antibody Conjugates
- Our next-generation Degrader Antibody Conjugates (DAC) are designed to improve safety and efficacy through advanced antibody and linker engineering
- DACs combine the tissue selectivity of antibody-mediated delivery with the well-validated catalytic mechanism of targeted protein degradation
- DACs offer opportunities to expand beyond conventional cytotoxic ADC payloads
9:30 am Developing AURKB PROTACs as a Novel Payload Class for Next-Generation Degrader Antibody Conjugates (DACs)
- Development of highly potent (<500 pM) AURKB PROTACs from legacy target binders
- Modification of PROTACs to allow for conjugation to DACs
- Assessment of what PROTAC physicochemical properties make for good DAC payloads
10:00 am Reprogramming Cell-Surface Protein Turnover for Autoimmune Disease
- Harnessing cell-surface E3 ligases to degrade pathogenic immune receptors
- Achieving potent, cell-selective target removal beyond conventional antibody blockade
- Sharing early mechanistic insights and considerations for degrader optimisation
10:30 am Proximity by Design: Harnessing Induced Proximity for Challenging Targets
11:00 am Morning Break & Networking Time
Pioneering Non-Degrading Mechanisms to Expand the Druggable Proteome & Create Therapeutic Options for a Wide Range of Indications with Unmet Need
11:45 am BrainTACs Enable Brain-Selective Inhibition of CNS Targets, with Reduced Peripheral Adverse Effects
- Overview Montara’s BrainOnly™ platform and how our two-drug combinations enable brain-selective pharmacology through spatially restricted induced proximity
- Detail progress on our lead asset, MTX-E1, for brain-selective mTOR inhibition
- Provide insight into expanding the platform to additional targets and indications using our heterobifunctional BrainTACs™ (Brain Targeting Chimeras) for brain-selective two-drug combinations
12:15 pm Locktacs for Intrinsically Disordered Proteins: First-in-Class p27 Molecular Glue Stabilizers
- First-in-class p27 molecular glue addressing CDK4/6 & CDK2 resistance
- Differentiated molecular glue mechanism resetting cell-cycle control
- Scalable platform unlocking a pipeline of historically “undruggable” oncology drivers
12:45 pm Lunch Break & Networking Time
Expanding the Therapeutic Horizon of Induced Proximity Modalities for Immunology, Neuroscience & Beyond to Bring Effective Treatment Options to More Patients
1:45 pm Phenotypic Screening to Identify & Optimize Protein Degraders for CNS Disorders Acting Through the Autophagy-Lysosome Pathway
- Keys to designing fruitful phenotypic screens for protein degraders
- Rapid hit prioritization to lead and lead optimization
- Insights into PK/PD for protein degraders
2:15 pm Molecular Glue Degraders Enhance CAPRIN1-Dependent Lysosomal Degradation of APP & Reduce Amyloid in Alzheimer’s Disease
- Discovery of small molecules that reduce intracellular APP and extracellular Aβ in AD patient’s derived iPSC-neurons
- The compounds bind at the CAPRIN1-APP interface and induce CAPRIN1-mediated lysosomal degradation of APP
- Systemic administration of a lead compound significantly reduces APP levels, Aβ production, and amyloid burden in the brains of 5xFAD mice
2:45 pm Chair’s Closing Remarks
Latest Tools & Technologies Track
7:30 am Check In & Refreshments
8:20 am Chair’s Opening Remarks
Effectively Implementing AI & Machine Learning to Design, Predict & Optimize Induced Proximity Molecules & Minimize Off-Target Effects
8:30 am Session Details to be Announced
9:00 am Target Discover & Validation Leveraging AI-Native Chimeric Ligands for Induced Proximity
- Utilization of Chimeric Ligands for Induced Proximity (CLIPs) target discovery and validation
- High throughput approaches to CLIP screening
- Virtuous circle of integration of AI models and high throughput screening
9:30 am Optimizing the Next Generation Degraders with Better Informatics, Descriptors & Predictive Modeling
- Development of internal tools to manage, visualize, and streamline the analysis of PROTAC and molecular glue molecules
- Evaluating the predictiveness of 2D/3D descriptors for PROTAC/Glue
- Development of ML model of EPSA to facilitate design of permeable PROTACs
10:00 am Discussion: Harnessing AI & Computational Modelling to Optimize Design, Specificity & Efficacy of Induced Proximity Molecules to Support the Development of Tolerable, Selective Therapies
- Optimizing PROTAC linkers & E3 ligase pairing with AI and machine learning tools for enhanced selectivity and potency
- Transforming molecular glue design with AI to predict target engagement, enhance selectivity and minimize off-target degradation
- Employing computational tools and modelling approaches to inform therapeutic strategy across induced proximity modalities
11:00 am Morning Break & Networking Time
Engineering High-Throughput Assays & Advanced Screening Libraries to Decode Mechanisms of Action & Enable the Discovery of Selective Induced Proximity Molecules
11:45 am Molecular Glue DEL Screening to Produce Expansive Datasets for Systematic Hit Identification for High Value Therapeutic Targets
- Development and implementation of a molecular glue DEL screening platform at scale
- Leveraging PPI for targets with high unmet medical need that have proven limited or intractable for ligand finding efforts
- A combination of approaches increases confidence in hit calling for off-DNA synthesis of hits and leads to improved validation
12:15 pm Molecular Glue Discovery & Validation Using DNA-Encoded Libraries
- Methods for the rational discovery of molecular glues using DNA-encoded libraries
- Methods for hit optimization and validation
- Case studies
12:45 pm Lunch Break & Networking Time
Applying Advanced Proteomics to Map Target Engagement & Off-Target Profiles Across Cell Types & Tissues
1:45 pm Scaling Proteomics for High-Throughput CRBN Target Discovery
- Scalable proteomics platform transitioning from TMT-based discovery to DIA-enabled high-throughput profiling
- Establishment of a platform to map the CRBN target space, extending neosubstrate recognition beyond the canonical β‑hairpin G‑loop degron
- Discovery of a molecular glue degrader MRT-31619, that drives homo-dimerization of CRBN and promotes its fast, potent, and selective degradation
2:15 pm GlueScope: Accelerating Molecular Glue Discovery through Orthogonal Proteomics & Deep Screening
- Building a high-throughput orthogonal proteomics platform integrating proximity, ubiquitination, and degradation profiling
- Expanding the druggable proteome through systematic screening across diverse E3 ligases and disease-relevant cell lineages
- Generating large-scale, AI-ready mechanistic datasets to accelerate molecular glue discovery, prioritization, and mechanism-of-action elucidation